Liang Hengrui, Deng Hongsheng, Liang Wenhua, Guo Kai, Gao Ziqing, Wiesel Ory, Flores Raja M, Song Kimberly, Redwan Bassam, Migliore Marcello, Li Shuben, Yin Weiqiang, He Jianxing
Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China.
Guangzhou Medical University, Guangzhou 510120, China.
Ann Transl Med. 2020 Mar;8(5):245. doi: 10.21037/atm.2020.01.118.
We present a case of a 56-year-old male patient with stage IIIB (T3N2M0) poorly differentiated squamous cell carcinoma of the lung. Four cycles of chemotherapy were first applied, and the patient had stable disease. However, the patient refused to receive radiotherapy, therefore second-line treatment chemotherapy combined with anti-PD-1 immunotherapy was applied. Partial response was reached at the 4 cycle of chemotherapy combined with anti-PD-1 immunotherapy. The neoadjuvant strategy was prolonged to 10 cycles but no significant change was observed on tumor size. The patient then underwent video-assisted thoracoscopic left lower lobectomy. Eight cycles of adjuvant PD-1 immunotherapy were applied postoperatively. Perioperative immunotherapy demonstrated good curative effect in this patient and no recurrence was observed at the clinic 40 months following surgery. Here we intend to explore the concept of immunotherapy combined with chemotherapy and surgery in neoadjuvant and adjuvant setting, and to investigate the possibility of extending this strategy in patients with stage IIIB non-small cell lung cancer (NSCLC).
我们报告一例56岁男性患者，患有IIIB期（T3N2M0）肺低分化鳞状细胞癌。首先应用了四个周期的化疗，患者病情稳定。然而，患者拒绝接受放疗，因此应用了二线治疗化疗联合抗PD-1免疫疗法。在化疗联合抗PD-1免疫疗法的第4周期达到部分缓解。新辅助治疗方案延长至10个周期，但肿瘤大小未观察到显著变化。然后患者接受了电视辅助胸腔镜下左肺下叶切除术。术后应用了八个周期的辅助性PD-1免疫疗法。围手术期免疫疗法在该患者中显示出良好的疗效，术后40个月门诊未观察到复发。在此，我们旨在探讨免疫疗法联合化疗和手术在新辅助和辅助治疗中的概念，并研究将该策略扩展至IIIB期非小细胞肺癌（NSCLC）患者的可能性。
